MAX Chat
Company Analysis BioNTech SE
1. Summary
Advantages
- The stock's return over the last year (19.77%) is higher than the sector average (-1.3%).
- Current debt level 1.13% is below 100% and has decreased over 5 years from 9.59%.
Disadvantages
- Price (104.92 $) is higher than fair price (66.75 $)
- Dividends (0%) are below the sector average (0.527%).
- The company's current efficiency (ROE=-3.36%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| BioNTech SE | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.3% | 9.1% | 1.2% |
| 90 days | 11.5% | 3.3% | 21.7% |
| 1 year | 19.8% | -1.3% | 21.8% |
BNTX vs Sector: BioNTech SE has outperformed the "Healthcare" sector by 21.07% over the past year.
BNTX vs Market: BioNTech SE has underperformed the market marginally by -1.99% over the past year.
Stable price: BNTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BNTX with weekly volatility of 0.3802% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (104.92 $) is higher than the fair price (66.75 $).
Price is higher than fair: The current price (104.92 $) is 36.4% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (24.73) is lower than that of the sector as a whole (64.15).
P/E vs Market: The company's P/E (24.73) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.35) is lower than that of the sector as a whole (18.96).
P/BV vs Market: The company's P/BV (1.35) is lower than that of the market as a whole (9.39).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (9.56) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (9.56) is lower than that of the market as a whole (10.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-45.75) is lower than that of the sector as a whole (274.79).
EV/Ebitda vs Market: The company's EV/Ebitda (-45.75) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -895.39% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-895.39%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-3.36%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-3.36%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-2.92%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-2.92%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (136.38%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (136.38%) is higher than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (5.13%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
